Sumary of Vonafexor induces improvements in liver fat content, kidney function in NASH:
- November 15, 2021 2 min read Source/Disclosures Published by: Source: Harrison SA, et al.
- Abstract L02. Presented at: The Liver Meeting Digital Experience;
- Back to Healio Vonafexor induced a strong reduction in liver fat content and improvements in biochemical and imaging markers of liver inflammation and kidney function, according to a presenter at The Liver Meeting Digital Experience.
- “The primary endpoint of hepatic fat decrease was met at week 12 in patients with presumed fibrosis treated with bone effects or 100 mg and 200 mg,” Stephen A.
- “There were consistent improvements of the noninvasive fibro inflammatory markers.
- “The dual effect seen in the study of both liver function improvement noninvasively and the renal improvement that was seen support further clinical and pathophysiological investigations in this population,” Harrison added.
- placebo Harrison, also honorary chair at the University of Oxford, and colleagues randomly assigned 96 patients with phenotype stage 2 or 3 fibrosis NASH to receive either daily oral placebo (PBO, n = 32) or vonafexor 100 mg (n = 31) or 200 mg (n = 33) for 12 weeks.
- Patients also had an absolute liver fat content of 10% or greater and liver stiffness by transient elastography 8.5 kPa or greater or previous biopsy-proven NASH.